Skip to main content
SpringerLink
Log in
Book cover

Novel Therapeutics from Modern Biotechnology

From Laboratory to Human Testing

  • Book
  • © 1999

Overview

Editors:
  1. Dale L. Oxender

    1. Parke-Davis Pharmaceutical Research, Ann Arbor, USA

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  2. Leonard E. Post

    1. Parke-Davis Pharmaceutical Research, Ann Arbor, USA

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  • Study Edition of the successful volume 137 in the Handbook of Experimental Pharmacology series * Original edition already sold out
  • Includes supplementary material: sn.pub/extras

Part of the book series: Handbook of Experimental Pharmacology (HEP, volume 137)

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 259.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 329.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (10 chapters)

  1. Front Matter

    Pages I-XVII
    Download chapter PDF

  2. Overview of Regulatory Expectations for Introducing Novel Therapies into Clinical Trials

    • J. A. Cavagnaro, M. A. Serabian
    Pages 1-12

  3. Preparation of Clinical Trial Supplies of Biopharmaceuticals

    • A. S. Lubiniecki, J. C. Erickson, C. L. Nolan, R. G. Scott, P. J. Shadle, T. M. Smith et al.
    Pages 13-31

  4. Proteins as Drugs: Analysis, Formulation and Delivery

    • C. R. Middaugh, R. Pearlman
    Pages 33-58

  5. Strategies for Dealing With the Immunogenicity of Therapeutic Proteins

    • M. L. Nucci, R. G. L. Shorr, A. Abuchowski
    Pages 59-88

  6. Targeted Toxin Hybrid Proteins

    • R. J. Kreitman, I. Pastan
    Pages 89-110

  7. SB 209763: A Humanized Monoclonal Antibody for the Prophylaxis and Treatment of Respiratory Syncytial Virus Infection

    • T. G. Porter, S. G. Griego, T. K. Hart, D. E. Everitt, S. B. Dillon
    Pages 111-129

  8. Preclinical Development of Antisense Therapeutics

    • A. A. Levin, S. P. Henry, C. F. Bennett, D. L. Cole, G. E. Hardee, G. S. Srivatsa
    Pages 131-163

  9. Formulation and Delivery of Nucleic Acids

    • H. E. J. Hofland, L. Huang
    Pages 165-192

  10. Safe, Efficient Production of Retroviral Vectors

    • H. Kotani, G. J. Mcgarrity
    Pages 193-219

  11. Clinical Systems for the Production of Cells and Tissues for Human Therapy

    • R. D. Armstrong, M. R. Koller, J. Maluta, W. C. Ogier
    Pages 221-241

  12. Back Matter

    Pages 243-248
    Download chapter PDF
Back to top

Keywords

About this book

A cover story of Business Week Magazine in January 1984 stated "Biotech Comes of Age". In February 1986, Venture Magazine had a cover article entitled "The Biotech Revolution is Here". This article went on to say "New Genetic Technologies Will Transform Our Lives". These announcements were made many years after the first biotechnology companies, such as Genentech, Cetus, Amgen and Biogen, were formed-to commercialize the "New Biology". . At the time of writing this book, there are over 1300 biotech companies developing new technologies or identifying potential biotech drugs. Most of these companies were started in the height of the "high-technology hype", although companies are still forming as the technology advances. A more recent survey showed only a relatively small number of Food and Drug Administration (FDA) approvals among over several hundred biotech­ nology products now in clinical trial. One could ask why it has taken so long to produce biotechnology products. Part of the reason is that each new class of biotech products brings with it a set of problems that need to be solved before they enter clinical trials. These problems are often unique to biotechnology products, such as peptides, proteins, monoclonal antibodies, nucleic acids and cellular therapies.

Editors and Affiliations

  • Parke-Davis Pharmaceutical Research, Ann Arbor, USA

    Dale L. Oxender, Leonard E. Post

Bibliographic Information

  • Book Title: Novel Therapeutics from Modern Biotechnology

  • Book Subtitle: From Laboratory to Human Testing

  • Editors: Dale L. Oxender, Leonard E. Post

  • Series Title: Handbook of Experimental Pharmacology

  • DOI: https://doi.org/10.1007/978-3-642-59990-3

  • Publisher: Springer Berlin, Heidelberg

  • eBook Packages: Springer Book Archive

  • Copyright Information: Springer-Verlag Berlin Heidelberg 1999

  • Hardcover ISBN: 978-3-540-65025-6Published: 04 December 1998

  • Softcover ISBN: 978-3-540-65927-3Published: 23 July 1999

  • eBook ISBN: 978-3-642-59990-3Published: 29 June 2013

  • Series ISSN: 0171-2004

  • Series E-ISSN: 1865-0325

  • Edition Number: 1

  • Number of Pages: XVII, 248

  • Number of Illustrations: 21 b/w illustrations, 3 illustrations in colour

  • Additional Information: Originally published as volume 137 in the series: Born,G.V.R.(Eds):Handbook of Experimental Pharmacology

  • Topics: Pharmacology/Toxicology, Immunology, Virology, Cell Biology, Molecular Medicine

Publish with us

Policies and ethics

Back to top

Search

Navigation